Runben Biotechnology (SH:603193) Xin Lang Cai Jing·2025-04-29 02:40Core Insights - The company reported a revenue of 1.318 billion yuan for 2024, representing a year-on-year increase of 27.61%, with a net profit of 300 million yuan, up 32.80% year-on-year [1] - The company experienced a strong performance in Q1 2025, with a revenue of 240 million yuan, reflecting a 44.00% year-on-year growth [1] Financial Performance - The gross margin for 2024 was 58.17%, an increase of 1.82 percentage points year-on-year, while the net profit margin was 22.77%, up 0.89 percentage points [2] - In Q1 2025, the gross margin decreased to 57.67%, down 1.98 percentage points year-on-year, and the net profit margin was 18.41%, a decline of 2.87 percentage points [2] Product Performance - The mosquito repellent series generated 439 million yuan in revenue for 2024, a 35.39% increase, accounting for 33.35% of total revenue [3] - The baby care series achieved 690 million yuan in revenue, up 32.42%, representing 52.39% of total revenue [3] - The essential oil series saw revenue of 158 million yuan, a 7.88% increase, while other products experienced a revenue decline of 25.51% [3] Sales Channels - Online direct sales contributed 774 million yuan in revenue for 2024, a 24.84% increase, making up 58.76% of total revenue [3] - The company has established a comprehensive sales network, integrating both online and offline channels, with significant market presence on platforms like Tmall, JD.com, and Douyin [5] R&D Investment - R&D expenses increased by 36.49% to 350.7 million yuan in 2024, reflecting the company's commitment to product innovation [4] - The company launched over 90 new or upgraded products, including children's sunscreen and other personal care items, to meet consumer needs [4]